Island Pharmaceuticals Expands Antiviral Pipeline Through Burnet Institute Collaboration
Island Pharmaceuticals Ltd (ASX: ILA) has entered a strategic research collaboration with the Burnet Institute to broaden the development potential of its antiviral candidates ISLA-101 and Galidesivir. The collaboration aims to evaluate the compounds against additional viral diseases, including measles, chikungunya, and Ross River virus.
The research program will leverage existing clinical and preclinical datasets to explore new therapeutic applications without requiring new molecule acquisition or significant additional capital investment. These targeted indications are aligned with global public health priorities and potential national stockpile and biodefence programs.
The work will be led by Dr Johanna Fraser of the Burnet Institute, a recognised expert in arbovirology and co-inventor of ISLA-101. Dr. Fraser recently secured a grant exceeding AU$780,000 from the National Health and Medical Research Council to support further research activities linked to the program.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Island Pharmaceuticals Expands Antiviral Pipeline Through Burnet Institute Collaboration
Island Pharmaceuticals Ltd (ASX: ILA) has entered a strategic research collaboration with the Burnet Institute to broaden the development potential of its antiviral candidates ISLA-101 and Galidesivir. The collaboration aims to evaluate the compounds against additional viral diseases, including measles, chikungunya, and Ross River virus.
The research program will leverage existing clinical and preclinical datasets to explore new therapeutic applications without requiring new molecule acquisition or significant additional capital investment. These targeted indications are aligned with global public health priorities and potential national stockpile and biodefence programs.
The work will be led by Dr Johanna Fraser of the Burnet Institute, a recognised expert in arbovirology and co-inventor of ISLA-101. Dr. Fraser recently secured a grant exceeding AU$780,000 from the National Health and Medical Research Council to support further research activities linked to the program.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au